Therapy for Pediatric Hodgkin Lymphoma

PHASE2CompletedINTERVENTIONAL
Enrollment

296

Participants

Timeline

Start Date

March 2, 2000

Primary Completion Date

May 31, 2012

Study Completion Date

November 5, 2021

Conditions
Hodgkin Lymphoma
Interventions
DRUG

12 Week Stanford V Chemotherapy

12 weeks of Stanford V chemotherapy plus low-dose, involved-field RT in children

DRUG

4 cycles of VAMP chemotherapy

4 cycles of VAMP chemotherapy alone in patients who achieve a complete response after 2 cycles of VAMP chemotherapy. For patients that do not achieve a complete response after 2 cycles of VAMP, they will receive low low-dose involved field radiotherapy at the end of all chemotherapy.

DRUG

2 alternating cycles of VAMP/COP chemotherapy

2 alternating cycles of VAMP/COP chemotherapy (total 4 cycles of chemotherapy) plus low-dose, involved-field RT.

DRUG

3 alternating cycles of VAMP/COP chemotherapy

3 alternating cycles of VAMP/COP chemotherapy (total 6 cycles of chemotherapy) plus low-dose, involved-field RT

Trial Locations (5)

38105

St. Jude Children's Research Hospital, Memphis

94304

Stanford University, Palo Alto

04102-3175

Maine Children's Cancer Program, Portland

02115

Dana Farber Cancer Institute, Boston

Massachusetts General Hospital, Boston

All Listed Sponsors
lead

St. Jude Children's Research Hospital

OTHER

NCT00145600 - Therapy for Pediatric Hodgkin Lymphoma | Biotech Hunter | Biotech Hunter